Table 2.
Summarized roles of the PERK signaling pathway
| Diseases | Switch of the PERK pathway | Neurological role | Summery | References |
|---|---|---|---|---|
| AD | PERK activation | Neurodegenerative | Detrimental | (48,49) |
| PERK inhibition | Reduced tauopathy | Beneficial | (67) | |
| p-eIF2α activation | Cell death | Detrimental | (54,60) | |
| PD | PERK inhibition | Neuroprotection | Beneficial | (75,139) |
| p-eIF2α activation | Neuroprotection | Beneficial | (71) | |
| HD | PERK inhibition | Neuroprotection | Beneficial | (81) |
| p-eIF2α activation | Neuronal death | Detrimental | ||
| Neuroprotection | Beneficial | (79) | ||
| PERK activation | Neuroprotection | Beneficial | (82) | |
| ALS | p-PERK activation | Motorneuron degeneration, muscle atrophy | Detrimental | (86,87) |
| p-eIF2α activation | ||||
| p-eIF2α activation | Prolong survivability | Beneficial | (89) | |
| PERK inhibition | Neuroprotection | Beneficial | (99,100) | |
| MS | PERK activation | cytoprotection | Beneficial | (35,36,38) |
| PERK inhibition | Loss of cyto/neuroprotective effects | Detrimental | (39,42) | |
| Tumor growth and cancer | p-eIF2α activation | Cancer initiation and progression | Detrimental | (105,112) |
| PERK activation | Decreased tumor growth/cell death | Beneficial | (116,120) | |
| Increased cell viability | Detrimental | (122) | ||
| Angiogenesis | Detrimental | (124) | ||
| PERK inhibition | Reduced metastasis | Beneficial | (130) |